CLINICAL AND IN VITRO EXPERIMENTAL STUDIES OF β-GALACTOSIDASE (S-2107) FOR INFANTILE DIARRHEA

概要

論文の詳細を見る
β-galactosidase (S-2107) derived from Penicillium Multicolor was administered to 15 infants with secondary lactose intolerance. An efficacy rate of 66.7% was obtained from overall clinical assessment. Lactose tolerance test with S-2107 was performed in 5 patients with infantile diarrhea. The mean glucose increment rate to the maximum level was 51.6±6.4% (M±SE). Compared to the reference drug GALANTASE, S-2107 showed a better lactose degradation rate at pH 3.0 and 6.0 in an in vitro experimental study using expressed human breast milk. Absorption test of S-2107 into the blood stream was examined by radio immunoassay. The result showed negative transfer in all serum samples from 3 infants 90 min after administration of S-2107. It was, theredore, concluded that S-2107 is an effective and safety enzyme for infants with secondary lactose intolerance. Application and safety of this enzyme to early infants and newborns were also discussed.
名古屋市立大学の論文
1984-07-24